CN102482282A - 多环化合物的新形式 - Google Patents

多环化合物的新形式 Download PDF

Info

Publication number
CN102482282A
CN102482282A CN2010800380284A CN201080038028A CN102482282A CN 102482282 A CN102482282 A CN 102482282A CN 2010800380284 A CN2010800380284 A CN 2010800380284A CN 201080038028 A CN201080038028 A CN 201080038028A CN 102482282 A CN102482282 A CN 102482282A
Authority
CN
China
Prior art keywords
crystalline form
compound
diffraction pattern
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800380284A
Other languages
English (en)
Chinese (zh)
Inventor
斯特芬·比尔梅尔
迈克尔·克里斯蒂
劳伦特·科沃希尔
R·斯科特·菲尔德
R·柯蒂斯·哈蒂万格
何林立
马丁·J·雅各布斯
迈克尔·克莱斯
罗伯特·E·麦凯恩
戴尔·R·莫雷
约瑟夫·佩特莱蒂斯
麦兰·雅兹达尼安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102482282(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN102482282A publication Critical patent/CN102482282A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800380284A 2009-08-26 2010-08-25 多环化合物的新形式 Pending CN102482282A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23718009P 2009-08-26 2009-08-26
US61/237,180 2009-08-26
PCT/US2010/046671 WO2011028580A1 (en) 2009-08-26 2010-08-25 Novel forms of a multicyclic compound

Publications (1)

Publication Number Publication Date
CN102482282A true CN102482282A (zh) 2012-05-30

Family

ID=43033463

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800380284A Pending CN102482282A (zh) 2009-08-26 2010-08-25 多环化合物的新形式

Country Status (19)

Country Link
US (1) US8633314B2 (enExample)
EP (1) EP2470540B1 (enExample)
JP (3) JP2013503173A (enExample)
KR (1) KR20120092100A (enExample)
CN (1) CN102482282A (enExample)
AU (1) AU2010289746B2 (enExample)
BR (1) BR112012004053A2 (enExample)
CA (1) CA2772328C (enExample)
CL (1) CL2012000478A1 (enExample)
DK (1) DK2470540T3 (enExample)
EA (1) EA020756B1 (enExample)
ES (1) ES2572652T3 (enExample)
IL (1) IL218132B (enExample)
MX (1) MX2012002456A (enExample)
MY (1) MY156873A (enExample)
NZ (1) NZ598883A (enExample)
SG (1) SG178852A1 (enExample)
UA (1) UA110604C2 (enExample)
WO (1) WO2011028580A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207511A (zh) * 2014-11-26 2017-09-26 赛福伦公司 Parp抑制剂的结晶形式
CN109632555A (zh) * 2018-12-28 2019-04-16 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010289746B2 (en) * 2009-08-26 2016-07-07 Cephalon, Inc. Novel forms of a multicyclic compound
PT3478286T (pt) 2016-06-29 2024-01-31 Tesaro Inc Métodos de tratamento do cancro do ovário
WO2018183354A1 (en) 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib compositions
EP3687505A1 (en) 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085686A2 (en) * 2000-05-09 2001-11-15 Cephalon, Inc. Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
CN101316592A (zh) * 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
AU2010289746B2 (en) * 2009-08-26 2016-07-07 Cephalon, Inc. Novel forms of a multicyclic compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085686A2 (en) * 2000-05-09 2001-11-15 Cephalon, Inc. Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
CN101316592A (zh) * 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANN W.NEWMAN,等: "Solid-state analysis of the active pharmaceutical ingredient in drug products", 《DRUG DISCOVERY TODAY》, vol. 8, no. 19, 31 October 2003 (2003-10-31), pages 898 - 905 *
张文婷，等: "聚腺苷二磷酸核糖聚合酶-1抑制剂药效团模型的建立", 《药学学报》, vol. 42, no. 3, 31 December 2007 (2007-12-31), pages 279 - 285 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207511A (zh) * 2014-11-26 2017-09-26 赛福伦公司 Parp抑制剂的结晶形式
CN109632555A (zh) * 2018-12-28 2019-04-16 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法

Also Published As

Publication number Publication date
IL218132B (en) 2018-02-28
EA201270315A1 (ru) 2012-08-30
DK2470540T3 (en) 2016-08-01
AU2010289746B2 (en) 2016-07-07
JP2013503173A (ja) 2013-01-31
US20120214998A1 (en) 2012-08-23
NZ598883A (en) 2014-09-26
SG178852A1 (en) 2012-04-27
EA020756B1 (ru) 2015-01-30
JP2018035158A (ja) 2018-03-08
HK1171750A1 (zh) 2013-04-05
KR20120092100A (ko) 2012-08-20
EP2470540B1 (en) 2016-04-20
AU2010289746A1 (en) 2012-04-12
BR112012004053A2 (pt) 2020-12-08
CA2772328A1 (en) 2011-03-10
MX2012002456A (es) 2012-05-08
CL2012000478A1 (es) 2012-11-05
WO2011028580A1 (en) 2011-03-10
CA2772328C (en) 2017-06-20
ES2572652T3 (es) 2016-06-01
US8633314B2 (en) 2014-01-21
UA110604C2 (uk) 2016-01-25
MY156873A (en) 2016-04-15
EP2470540A1 (en) 2012-07-04
JP2016014029A (ja) 2016-01-28
IL218132A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
JP2018035158A (ja) 多環系化合物の新規形態
US11168057B2 (en) Polymorphs and co-crystals of roxadustat
JP2013047238A (ja) ダサチニブ多形体およびその調製プロセス
PH12012500168B1 (en) Crystalline solvates and complexes of (is)-1,5-anhydro-l-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
KR20180011783A (ko) 삼나트륨 발사르탄:사쿠비트릴의 고체 형태
CA3022250A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
EP3344607A1 (en) Solid state forms of selexipag
EP2729470B1 (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
WO2012066565A2 (en) Asenapine maleate amorphous and crystalline form and process for preparation thereof
TW202409008A (zh) 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體
CN119212696A (zh) [2-(1h-吲哚-3-基)-1h-咪唑-4-基](3,4,5-三甲氧基)甲酮和其盐的多晶型物
TWI773987B (zh) 二胺基嘧啶類化合物或其水合物的固體形式及其製備方法和用途
JP2009513582A (ja) ４−オキソ−１−（３置換フェニル）−１，４−ジヒドロ−１，８−ナフチリジン−３−カルボキサミドホスホジエステラーゼ４阻害剤及びその製造方法
CN111484489B (zh) 无定形的b-raf激酶二聚体抑制剂
WO2023042214A1 (en) Solid state forms of relugolix
HK1171750B (en) Novel forms of a multicyclic compound
CN111484488A (zh) 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
WO2004089281A2 (en) Novel polymorphs of tolterodine tartrate
MX2011005055A (es) Nuevas formas de un compuesto de indazolo [5,4-a]pirrolo[3,4-c]car bazol.
CN102239163A (zh) 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法
AU2018201013B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
CN119859139A (zh) 双盐酸安罗替尼的固体形式及其制备方法
CN105949182A (zh) 阿齐沙坦酯的晶型及其制备方法
EA047214B1 (ru) СТАБИЛЬНЫЕ ТВЕРДЫЕ ДИСПЕРСИИ ИНГИБИТОРА ДИМЕРА КИНАЗЫ B-Raf, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ
HK1195900B (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120530